

IAP7 Rec'd PCT/PTO 23 JUN 2006

Express Mail Label No. EV 325 822 685 US

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. §371		Attorney Docket Number 57070-8020.US00 U.S. Application No. (if known, see 37 CFR §1.5) 10/584114
International Application No. PCT/US2004/043249	International Filing Date 20 December 2004	Priority Date Claimed 24 December 2003
Title of Invention TRIPTOLIDE 5,6-DERIVATIVES AS IMMUNOMODULATORS AND ANTICANCER AGENTS		
Applicant(s) for DO/EO/US Pharmagenesis, Inc.		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information		
1.	<input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. §371.	
2.	<input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. §371.	
3.	<input type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. §371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. §371(b) and PCT Articles 22 and 39(1).	
4.	<input type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.	
5.	<input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. §371(c)(2)). a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).	
6.	<input type="checkbox"/> A translation of the International Application into English (35 U.S.C. §371(c)(2)).	
7.	<input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)). a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input checked="" type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made.	
8.	<input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).	
9.	<input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. §371(c)(4)) (unsigned)	
10.	<input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. §371(c)(5)).	
Items 11. to 16. below concern document(s) or information included:		
11.	<input type="checkbox"/> An Information Disclosure Statement under 37 CFR §1.97 and §1.98.	
12.	<input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR §3.28 and §3.31 is included.	
13.	<input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSTITUTE preliminary amendment.	
14.	<input type="checkbox"/> A substitute specification.	
15.	<input type="checkbox"/> A change of Power of Attorney and/or Address letter.	
16.	<input type="checkbox"/> Other items or information:	

U.S. Application No. (if known, see 37 CFR §1.5)	International Application No.			Attorney's Docket No.
10/584114	PCT/US2004/043249			57070-8020.US00
17. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS PTO USE ONLY
BASIC NATIONAL FEE (37 CFR §1.492(a)(1)-(5):				
Basic National Stage Fee \$300.00 National Stage Search Fee \$500.00 National Stage Examination Fee \$200.00				
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$1700.00
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claim priority date (37 CFR §1.492(e)).				\$ 00.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	30 - 20 =	10	10 × \$ 50.00	\$ 500.00
Independent Claims	4 - 3 =	1	1 × \$200.00	\$ 200.00
Multiple Dependent Claim(s) (if applicable)			+ \$360.00	\$ 00.00
TOTAL OF ABOVE CALCULATIONS =				\$1700.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.				\$ 850.00
SUBTOTAL =				\$ 850.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR §1.942(f)). +				\$
Fee for recording enclosed assignment (37 CFR §1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR §3.28, §3.31) \$40.00 per property. +				\$ 00.00
TOTAL FEES ENCLOSED =				\$ 850.00
Amount To Be:				refunded
Amount to Be:				charged
a. <input type="checkbox"/>	A check in the amount of \$*** to cover the filing fees is enclosed.			
b. <input checked="" type="checkbox"/>	Please charge Deposit Account No. 50-2207 in the amount of \$850 to cover the above fees.			
c. <input checked="" type="checkbox"/>	The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-2207.			
NOTE: Where an appropriate time limit under 37 CFR §1.494 or §1.495 has not been met, a petition to revive (37 CFR 137(a) or (b)) must be filed and granted to restore the application to pending status.				
SEND ALL CORRESPONDENCE TO: Perkins Coie LLP P.O. Box 2168 Menlo Park, CA 94026 Customer No. 22918				
 Signature Brian S. Boyer Registration No. 52,643				

10/584114

Attorney Docket No. 57070-8020.US00

AP3 Rec'd PCT/PTO 23 JUN 2006

**IN THE UNITED STATES OF AMERICA AS AN ELECTED
OFFICE (EO/US)**

IN RE APPLICATION OF: Dai et al.

APPLICATION No.: Not Yet Assigned

PCT FILING DATE: December 20, 2004

PRIORITY DATE: DECEMBER 24, 2003

TITLE: TRIPTOLIDE 5,6-DERIVATIVES AS IMMUNOMODULATORS
AND ANTICANCER AGENTS

CERTIFICATE OF MAILING BY EXPRESS MAIL

Mail Stop PCT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450
Attn: DO/EO/US

Sir:

Express Mail Label No: EV 325 822 685 US

Date of Deposit: June 23, 2006

I hereby certify that the attached filing: application transmittal under 35 U.S.C. §371, a Declaration of the Inventors under 35 U.S.C. §371 (unsigned), and a check for fees due, are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents, Mail Stop PCT, P. O. Box 1450, Alexandria, VA 22313-1450, Attention: DO/EO/US.

Respectfully submitted,
Perkins Coie LLP

Date: 6-23-06

Lynnea B. Kennelly
Printed Name: Lynnea B. Kennelly

Correspondence Address:
Customer No. 22918
650 838-4300